Obesity drugs #

Trial-level efficacy, sales, forward calendar, and full pipelines across the seven sponsors racing for GLP-1, amylin, and combination obesity drugs.

As of 2026-07-03. Updated as catalysts move.

17 days
Next thesis-moving catalyst Both: 100% pharma import tariff effective (MFN exemption) Jul 31, 2026
6
approved obesity drugs
4
in Phase 3 (incl. filed)
-28.3%
best weight loss to date
(Retatrutide, TRIUMPH-1)
€6.4B
obesity SKU revenue
(Q1 2026)

Compare drugs

Weight-loss trajectories, efficacy vs tolerability, and a sortable data table - one filter and estimand toggle across every obesity drug.

Open the explorer →

Pipeline & indications

Every disclosed asset by sponsor and phase, plus the beyond-weight-loss indication matrix (CV, MASH, CKD, OSA, HFpEF).

See the pipeline →

Sales

Quarterly revenue per obesity SKU in EUR - how the commercial race between Wegovy, Zepbound, and the oral entrants tracks.

View sales →

Calendar

Forward catalysts - earnings, trial readouts, and FDA decisions - ordered by date and tiered by stock impact.

See the calendar →

Latest blog: China's Obesity Drugs Look Best-in-Class - and the West Is Already Buying Them (2026-07-06) · more posts tagged obesity